Recently, Sabrina Ehnert and colleagues from Tuebingen University (Germany) published a comprehensive review about hepatic osteodystrophy (Ehnert et al. 2019) . Currently, numerous studies focus on a better understanding of liver disease (Jansen et al. 2017; Vartak et al. 2016; Nussler et al. 2014; Hammad et al. 2018 ) and mechanisms of hepatotoxicity (Grinberg et al. 2014 (Grinberg et al. , 2018 Schenk et al. 2017; Godoy et al. 2013 Godoy et al. , 2015 Hammad et al. 2017 Hammad et al. , 2018 Kodidela et al. 2017; Leist et al. 2017 ). However, relatively little is known how disturbed liver functions influence other organs. The majority of patients with chronic liver diseases suffer from hepatic osteodystrophy (Nakchbandi and van der Merwe 2009; Diamond et al. 1990; Wibaux et al. 2011; Tsai et al. 2013; Nussler et al. 2014) . Hepatic osteodystrophy increases the risk of bone fractures which are difficult to treat and affect the long-term prognosis of patients (Angulo et al. 2011; Guañabens et al. 2010; Guarino et al. 2016; Goel and Kar 2010) . In the present review, Ehnert and colleagues summarize and discuss current knowledge of the molecular mechanisms responsible for hepatic osteodystrophy:
• Compromised vitamin D metabolism.
• Alterations in transforming growth factor beta (TGF-β)-induced effects.
• Compromised bone morphogenetic protein (BMP) signaling.
• Altered expression of histone deacetylases (HDACs).
• Functional loss mutations of sclerostin.
Based on these mechanisms, the authors discuss therapeutic perspectives and possibilities or early diagnosis. The article is a must-read for anyone interested in the mechanisms how liver diseases compromise bone metabolism.
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